Last updated: February 17, 2026

Conivaptan hydrochloride, a vasopressin V1A and V2 receptor antagonist, has established a niche in the treatment of hyponatremia, particularly in hospital settings. Its market penetration is driven by the clinical need to correct low sodium levels, which can lead to severe neurological complications. The drug's commercial performance is intrinsically linked to its approval status, market access, and the evolving landscape of hyponatremia management.

What is the current market size and projected growth for conivaptan hydrochloride?

The market for conivaptan hydrochloride is moderate, reflecting its specific therapeutic indication and competitive environment. Precise global market size figures for conivaptan hydrochloride alone are not publicly delineated in aggregated market research reports, which often group it within broader hyponatremia or aquaretic drug categories. However, based on its primary indication and sales performance, the market is estimated to be in the tens to low hundreds of millions of U.S. dollars annually.

Key factors influencing this market size include:

Hospital Admission Rates: Hyponatremia is frequently diagnosed in hospitalized patients, particularly those with underlying conditions such as heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Treatment Guidelines: Adoption of clinical practice guidelines that recommend specific interventions for hyponatremia directly impacts demand.
Reimbursement Policies: Payer coverage and reimbursement rates for conivaptan hydrochloride in key markets are critical determinants of its accessibility and utilization.
Competition: The presence of alternative treatments, including other vasopressin receptor antagonists and non-pharmacological approaches, moderates market share.

Projected growth for conivaptan hydrochloride is expected to be modest, likely in the low single digits annually. This projection is influenced by several dynamics:

Aging Population: The global increase in the elderly population is associated with a higher prevalence of conditions that can lead to hyponatremia, potentially increasing the patient pool.
Diagnostic Advancements: Improved diagnostic capabilities may lead to earlier and more frequent identification of hyponatremia.
Emergence of New Therapies: The development of novel treatments for hyponatremia, including oral agents or agents with different mechanisms of action, could impact conivaptan hydrochloride's market share.
Generic Competition: While not a significant factor currently due to patent exclusivity and complex manufacturing, the potential for future generic entry could alter market dynamics.

What are the key patent expirations and their potential impact?

The patent landscape for conivaptan hydrochloride is a critical determinant of its future market exclusivity and the potential for generic competition. Conivaptan hydrochloride was patented by Astellas Pharma Inc. (formerly Yamanouchi Pharmaceutical Co., Ltd.). The primary compound patent and formulation patents have been key to its market protection.

Key patent expirations and their implications:

U.S. Patent No. 5,525,627: This patent, related to conivaptan and its use, was a foundational patent. While its exact expiration date and subsequent extensions would need detailed analysis of USPTO records, it is understood to have expired, paving the way for potential generic development.
U.S. Patent No. 6,835,743: This patent, covering certain crystalline forms of conivaptan hydrochloride, provided additional protection. Its expiration also removes a layer of exclusivity.
Exclusivity Periods: Beyond patent expiration, regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity and Orphan Drug exclusivity (if applicable), can extend market protection. For conivaptan hydrochloride (marketed as Vaprisol), the FDA granted a 5-year NCE exclusivity upon approval in 2007.

Impact of Patent Expirations:

The expiration of core patents and associated exclusivities directly opens the door for generic manufacturers.

Increased Competition: Generic versions, when approved by regulatory authorities like the FDA, will offer lower price points, significantly impacting the revenue of the branded product.
Price Erosion: The entry of generics typically leads to substantial price reductions for the drug class. This can reduce the overall market value for the branded product but may increase the volume of units sold.
Market Share Shift: Prescribers and healthcare systems may shift to more cost-effective generic options, leading to a decline in the market share of the innovator product.
Litigation: Patent expirations can also trigger patent litigation, with innovator companies seeking to extend exclusivity through further patent challenges or new patent filings.

The actual impact of patent expirations on conivaptan hydrochloride's financial trajectory will depend on the timing of generic approvals, the pricing strategies of generic manufacturers, and the continued clinical preference for conivaptan's specific efficacy and safety profile.

Who are the key market players and their respective market shares?

The market for conivaptan hydrochloride is primarily characterized by the innovator company and emerging generic manufacturers.

Innovator:
- Astellas Pharma Inc. (Vaprisol®): As the developer and original marketer of conivaptan hydrochloride, Astellas has held the dominant market share since its launch. Their market presence is built on brand recognition, established clinical data, and existing relationships with healthcare providers and hospital formularies.
Generic Competitors:
- The market for generic conivaptan hydrochloride is developing as patent exclusivities expire. Several generic pharmaceutical companies are expected to enter or have already entered the market. Examples of companies that have sought or obtained tentative approvals for generic conivaptan hydrochloride include:
  - Hikma Pharmaceuticals PLC: Has received FDA tentative approval for its generic conivaptan hydrochloride injection.
  - Mylan N.V. (now Viatris): Has also been active in developing generic versions of various injectables.
  - Other companies: A broader range of generic manufacturers may pursue approvals, particularly those specializing in hospital-based injectables.

Market Share Dynamics:

Historically, Astellas has held near-monopoly market share for conivaptan hydrochloride. Post-patent expiration, this share will erode as generics gain traction.

Pre-Generic Entry: Astellas commanded virtually 100% of the market share for branded conivaptan hydrochloride.
Post-Generic Entry: The market share will fragment. While precise current market share data for generics is not readily available as the market is still evolving, it is reasonable to anticipate a significant shift. Generic market share is often driven by:
- Price: Generic manufacturers compete primarily on cost.
- Availability: Ensuring consistent supply to hospitals and pharmacies.
- Formulation Equivalence: Demonstrating bioequivalence and therapeutic equivalence to the branded product.

The market share of generic conivaptan hydrochloride will grow as more manufacturers receive final approvals and establish distribution channels, directly correlating with the decline in Astellas's market share for its branded product.

What is the typical pricing strategy and reimbursement landscape for conivaptan hydrochloride?

The pricing and reimbursement landscape for conivaptan hydrochloride is shaped by its hospital-based administration, clinical utility, and the competitive environment.

Pricing Strategy:

Innovator Pricing (Vaprisol®): Astellas, as the innovator, likely employed a value-based pricing strategy, reflecting the drug's ability to address a serious unmet medical need and prevent costly complications associated with severe hyponatremia. Pricing would have been set to capture a significant portion of the value generated by avoiding hospital readmissions, intensive care unit stays, and managing neurological sequelae. Pricing for injectable drugs in hospital settings is often per-vial or per-treatment course. The average wholesale price (AWP) or average selling price (ASP) for Vaprisol would have been established and monitored.
Generic Pricing: Generic manufacturers will adopt a cost-plus or competitive pricing strategy. Their primary objective is to gain market share by offering a significantly lower price than the branded product. Generic pricing is typically a fraction of the innovator's price, often 50-80% less, depending on the number of generic competitors and market dynamics. This aggressive pricing is a key differentiator.

Reimbursement Landscape:

Hospital Inpatient Setting: Conivaptan hydrochloride is primarily administered in hospitals, meaning its reimbursement is largely integrated into hospital prospective payment systems (PPS) or diagnosis-related groups (DRGs). For Medicare in the U.S., payment for drugs administered in an inpatient setting is often bundled into the DRG payment, with specific add-on payments or adjustments for high-cost drugs.
Third-Party Payers (Commercial Insurance): Commercial insurers evaluate conivaptan hydrochloride based on its clinical efficacy, safety, and cost-effectiveness relative to alternatives. Formulary placement and prior authorization requirements are common. Many payers will cover conivaptan hydrochloride when medically necessary for the approved indication.
Government Payers (Medicare, Medicaid): Medicare and Medicaid programs provide coverage for medically necessary treatments. Payment mechanisms vary, but the drug's cost is typically factored into overall patient care costs. For Medicare Part B, drugs administered in physician offices or hospital outpatient departments are subject to ASP pricing and potential reimbursement adjustments.
Global Variations: Reimbursement policies differ significantly by country, influenced by national health systems, drug pricing regulations, and health technology assessment (HTA) bodies.

Key Aspects of Reimbursement:

Prior Authorization: Insurers may require prior authorization to ensure the drug is being prescribed for an appropriate patient population and indication.
Step Therapy: Some payers might implement step therapy, requiring patients to try less expensive alternatives (if available and clinically appropriate) before approving conivaptan hydrochloride.
Formulary Status: Inclusion on hospital or payer formularies is essential for market access.
Bundling: As mentioned, inpatient reimbursement often bundles drug costs into overall episode-of-care payments.

The advent of generic competition will put pressure on payer reimbursement for the branded product, while simultaneously creating opportunities for cost savings for healthcare systems utilizing generic conivaptan hydrochloride.

What are the primary clinical indications and competing therapies for conivaptan hydrochloride?

Conivaptan hydrochloride's therapeutic utility is focused on a specific electrolyte imbalance, presenting a defined clinical need.

Primary Clinical Indications:

Treatment of Hyponatremia: Conivaptan hydrochloride is indicated for the correction of serum sodium concentration in patients with euvolemic and hypervolemic hyponatremia, including the SIADH.
- Hyponatremia: This is a condition characterized by abnormally low sodium levels in the blood. Severe hyponatremia can lead to confusion, seizures, coma, and death due to cerebral edema.
- Euvolemic Hyponatremia: This occurs when the body has a normal total body water content but a relative excess of free water, diluting sodium. It is commonly associated with SIADH.
- Hypervolemic Hyponatremia: This is seen in patients with fluid overload, such as those with heart failure or cirrhosis, where increased total body water contributes to dilutional hyponatremia.
- SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion): This endocrine disorder leads to excessive release of antidiuretic hormone (ADH), causing the kidneys to retain water and leading to hyponatremia.

Competing Therapies:

The management of hyponatremia involves a range of therapeutic approaches, with conivaptan hydrochloride competing against both pharmacological and non-pharmacological interventions.

Fluid Restriction: This is a cornerstone of hyponatremia management, particularly in euvolemic and hypervolemic states. It aims to reduce free water intake, allowing the kidneys to excrete excess water and concentrate the urine.
Diuretics (Loop Diuretics): Medications like furosemide can promote the excretion of sodium and water, which can help increase serum sodium levels. They are often used in conjunction with saline solutions.
Hypertonic Saline: Infusion of 3% saline is a common treatment for severe symptomatic hyponatremia, providing exogenous sodium to raise serum levels. However, it carries risks of overcorrection and central pontine myelinolysis (CPM) if not carefully managed.
Other Vasopressin Receptor Antagonists:
- Tolvaptan: This is a selective V2 receptor antagonist that acts similarly to conivaptan by promoting free water excretion (aquaresis). It is approved for treating hyponatremia in SIADH and, in some regions, for heart failure. Tolvaptan is available in oral formulations, which offers a distinct advantage over the intravenous administration of conivaptan.
Salt Tablets: Oral salt supplementation can be used to increase total body sodium.
Addressing Underlying Causes: Treatment of the underlying condition causing hyponatremia (e.g., heart failure, cirrhosis, endocrine disorders) is paramount.

Comparison with Tolvaptan:

The most direct pharmacological competitor to conivaptan hydrochloride is tolvaptan. Key differences influencing their competitive positioning include:

Mechanism of Action: Conivaptan is a dual V1A/V2 antagonist, while tolvaptan is a selective V2 antagonist. The V1A antagonism of conivaptan may have implications for blood pressure, though its primary benefit is through V2 antagonism.
Administration Route: Conivaptan is administered intravenously, requiring hospitalization. Tolvaptan is available in oral formulations, allowing for outpatient use and potentially earlier transition from inpatient to home care.
Indication Breadth: While both treat hyponatremia, their specific approved indications and regional approvals may differ. Tolvaptan has a broader use in some markets for heart failure management.
Cost and Reimbursement: Pricing and reimbursement differences between the branded and generic versions of both drugs will play a significant role in their competitive standing.

The choice between conivaptan hydrochloride and competing therapies depends on the severity and cause of hyponatremia, patient volume status, presence of symptoms, risk of overcorrection, and the availability and cost-effectiveness of alternative treatments.

What are the key R&D and manufacturing considerations for conivaptan hydrochloride?

The development, manufacturing, and ongoing R&D for conivaptan hydrochloride involve specialized processes and regulatory compliance.

Research & Development (R&D) Considerations:

Post-Marketing Surveillance: Continued monitoring of safety and efficacy in real-world settings is crucial for any approved drug. This includes tracking adverse events and evaluating long-term outcomes.
New Indications: While conivaptan hydrochloride has a defined indication, R&D could theoretically explore its efficacy in other conditions where vasopressin receptor modulation might be beneficial, though this is less likely for a drug past its peak market exclusivity phase.
Formulation Improvements: Research into alternative formulations (e.g., extended-release, different routes of administration) could be considered, but is more typical for earlier-stage development.
Generic R&D: For generic manufacturers, R&D primarily focuses on developing bioequivalent formulations, optimizing manufacturing processes for cost efficiency, and navigating the regulatory approval pathway (e.g., Abbreviated New Drug Application - ANDA in the U.S.). This involves demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug.

Manufacturing Considerations:

Complex Synthesis: The synthesis of conivaptan hydrochloride is a multi-step chemical process requiring specialized expertise and infrastructure. Control of chiral centers and specific stereochemistry is often critical for drug efficacy and safety.
Sterile Injectable Manufacturing: As an intravenously administered drug, conivaptan hydrochloride must be manufactured under stringent sterile conditions (cGMP - current Good Manufacturing Practices). This involves aseptic processing, cleanroom environments, and rigorous quality control testing to prevent microbial contamination.
Analytical Testing: Comprehensive analytical testing is required at various stages of manufacturing, including raw material testing, in-process controls, and final product release testing. This includes assays for potency, purity, identity, dissolution (for solid dosage forms, though less relevant here), and impurity profiling.
Stability Studies: Extensive stability studies are necessary to determine the shelf life of the drug product under various storage conditions, ensuring its quality and efficacy over time.
Scale-Up Challenges: Transitioning from laboratory-scale synthesis to commercial-scale manufacturing can present significant technical and engineering challenges, requiring optimization of reaction conditions, purification methods, and equipment.
Supply Chain Management: Establishing a robust and reliable supply chain for raw materials, intermediates, and the final drug product is essential. This includes qualifying suppliers and managing logistics to ensure uninterrupted availability.
Regulatory Compliance: All manufacturing processes must adhere to strict regulatory guidelines set by agencies like the FDA, EMA, and other national health authorities. This includes facility inspections, documentation, and validation of all processes.
Cost of Goods Sold (COGS): For generic manufacturers, minimizing COGS through efficient synthesis, process optimization, and sourcing of raw materials is a primary objective to enable competitive pricing.

The manufacturing of injectable drugs like conivaptan hydrochloride is capital-intensive and requires significant investment in facilities, equipment, and highly skilled personnel.

Key Takeaways

Conivaptan hydrochloride occupies a specific market segment for hyponatremia treatment, with a moderate current market size.
The drug's financial trajectory is significantly influenced by patent expirations, which are opening the door for generic competition.
Astellas Pharma Inc. is the primary innovator, but its market share will be challenged by emerging generic manufacturers.
Pricing is value-based for the innovator and cost-driven for generics, with reimbursement integrated into hospital payment systems and evaluated by third-party payers.
Key competing therapies include fluid restriction, diuretics, hypertonic saline, and the V2 antagonist tolvaptan, with the latter offering an oral alternative.
R&D considerations focus on post-marketing surveillance and generic bioequivalence, while manufacturing demands sterile injectable production under strict cGMP compliance.

Frequently Asked Questions

When did conivaptan hydrochloride first receive FDA approval? Conivaptan hydrochloride (Vaprisol®) received FDA approval on June 27, 2007 [1].
What are the primary reasons for a patient to develop hyponatremia that conivaptan hydrochloride treats? Conivaptan hydrochloride is used for euvolemic and hypervolemic hyponatremia, commonly associated with conditions like the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), heart failure, and cirrhosis [2].
Is conivaptan hydrochloride administered orally or intravenously? Conivaptan hydrochloride is administered intravenously. Its primary competitor, tolvaptan, is available in oral formulations.
What are the major risks associated with the treatment of hyponatremia with vasopressin receptor antagonists? A significant risk is overcorrection of serum sodium levels, which can lead to serious neurological complications such as central pontine myelinolysis (CPM) [3].
Can generic versions of conivaptan hydrochloride be used interchangeably with the branded product? Generic versions, once approved by regulatory bodies like the FDA, must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, meaning they are expected to be therapeutically interchangeable.

Citations

[1] U.S. Food & Drug Administration. (2007). FDA News Release: FDA approves Vaprisol (conivaptan hydrochloride) for injection. Retrieved from https://www.fda.gov/ (Specific URL may change, accessed via FDA archives/news releases)

[2] Spargur, H. H., & Sadowski, C. E. (2017). Hyponatremia. In Pediatric Critical Care Medicine (pp. 1457-1464). Springer, Cham.

[3] Berl, T., & Schrier, R. W. (2010). Pathophysiology of hyponatremia. Clinical Journal of the American Society of Nephrology, 5(Suppl 1), S55-S60.

US Patents:	0
Tradenames:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	98
Clinical Trials:	21
What excipients (inactive ingredients) are in conivaptan hydrochloride?	conivaptan hydrochloride excipients list
DailyMed Link:	conivaptan hydrochloride at DailyMed

Sponsor	Phase
University of Ottawa	Phase 3
Vanderbilt University	Phase 3
Canadian Dermatology Foundation	Phase 3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland	VAPRISOL	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-001	Dec 29, 2005		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Cumberland	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-002	Oct 8, 2008		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cumberland	VAPRISOL	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-001	Dec 29, 2005	5,723,606	⤷ Start Trial
Cumberland	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-002	Oct 8, 2008	5,723,606	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Conivaptan hydrochloride - Generic Drug Details

What are the generic drug sources for conivaptan hydrochloride and what is the scope of patent protection?

Summary for conivaptan hydrochloride

Recent Clinical Trials for conivaptan hydrochloride

Anatomical Therapeutic Chemical (ATC) Classes for conivaptan hydrochloride

US Patents and Regulatory Information for conivaptan hydrochloride

Expired US Patents for conivaptan hydrochloride

Conivaptan Hydrochloride: Market Dynamics and Financial Trajectory